Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Effect of biofeedback and deep oscillation on Raynaud's phenomenon secondary to systemic sclerosis: results of a controlled prospective randomized clinical trial.

Sporbeck B, Mathiske-Schmidt K, Jahr S, Huscher D, Becker M, Riemekasten G, Taufmann I, Burmester GR, Pögel S, Reisshauer A.

Rheumatol Int. 2012 May;32(5):1469-73. doi: 10.1007/s00296-011-1882-2. Epub 2011 Apr 8.

PMID:
21476099
2.

Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.

Motegi S, Yamada K, Toki S, Uchiyama A, Kubota Y, Nakamura T, Ishikawa O.

J Dermatol. 2016 Jan;43(1):56-62. doi: 10.1111/1346-8138.13030. Epub 2015 Jul 15.

PMID:
26173902
3.

Efficacy of cilostazol for the treatment of Raynaud's phenomenon in systemic sclerosis patients.

Negrini S, Spanò F, Penza E, Rollando D, Indiveri F, Filaci G, Puppo F.

Clin Exp Med. 2016 Aug;16(3):407-12. doi: 10.1007/s10238-015-0370-5. Epub 2015 Jun 19.

PMID:
26088182
4.

Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.

Abou-Raya A, Abou-Raya S, Helmii M.

J Rheumatol. 2008 Sep;35(9):1801-8. Epub 2008 Aug 15.

PMID:
18709692
5.

Behavioral treatment of Raynaud's phenomenon in scleroderma.

Freedman RR, Ianni P, Wenig P.

J Behav Med. 1984 Dec;7(4):343-53.

PMID:
6520866
6.

Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.

Selenko-Gebauer N, Duschek N, Minimair G, Stingl G, Karlhofer F.

Rheumatology (Oxford). 2006 Oct;45 Suppl 3:iii45-8. Erratum in: Rheumatology (Oxford). 2008 Feb;47(2):234-5.

PMID:
16987835
7.
8.

Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.

Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E, Arpaia G, Sardina M, Origgi L, Vanoli M.

Clin Exp Rheumatol. 2001 Sep-Oct;19(5):503-8.

PMID:
11579708
9.

Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.

Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, Black CM.

Arthritis Rheum. 1999 Dec;42(12):2646-55.

10.

Use of biofeedback training in treatment of Raynaud's disease and phenomenon.

Yocum DE, Hodes R, Sundstrom WR, Cleeland CS.

J Rheumatol. 1985 Feb;12(1):90-3.

PMID:
3981523
11.

[Recent advances in Raynaud's syndrome].

Klein-Weigel P.

Dtsch Med Wochenschr. 2012 Mar;137(13):622-4. doi: 10.1055/s-0031-1298986. Epub 2012 Mar 20. German. No abstract available.

PMID:
22434167
12.

Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jiménez SA, White B, Seibold JR, Wigley FM; Scleroderma Clinical Trials Consortium.

Arthritis Rheum. 2002 Sep;46(9):2410-20.

13.

[Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial].

Correa MJ, Mariz HA, Andrade LE, Kayser C.

Rev Bras Reumatol. 2014 Nov-Dec;54(6):452-8. doi: 10.1016/j.rbr.2014.07.001. Epub 2014 Aug 27. Portuguese.

14.

Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.

Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR.

Arthritis Rheum. 1998 Apr;41(4):670-7.

PMID:
9550476
15.

Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.

Kumar U, Sankalp G, Sreenivas V, Kaur S, Misra D.

Rheumatol Int. 2013 Apr;33(4):1047-52. doi: 10.1007/s00296-012-2466-5. Epub 2012 Jul 26. Erratum in: Rheumatol Int. 2013 Apr;33(4):1053. Gokhle, Sankalp S [corrected to Sankalp, Gokhale].

PMID:
22833239
16.

Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis.

Schiopu E, Hsu VM, Impens AJ, Rothman JA, McCloskey DA, Wilson JE, Phillips K, Seibold JR.

J Rheumatol. 2009 Oct;36(10):2264-8. doi: 10.3899/jrheum.090270. Epub 2009 Sep 15.

PMID:
19755613
17.

Sex and time to diagnosis in systemic sclerosis: an updated analysis of 1,129 patients from the Canadian scleroderma research group registry.

Delisle VC, Hudson M, Baron M, Thombs BD, And The Canadian Scleroderma Research Group A.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-10-4. Epub 2013 Oct 11.

PMID:
24144459
18.

Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study.

Sambo P, Amico D, Giacomelli R, Matucci-Cerinic M, Salsano F, Valentini G, Gabrielli A.

J Rheumatol. 2001 Oct;28(10):2257-62.

PMID:
11669166
19.

[Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].

Serri J, Legré R, Veit V, Guardia C, Gay AM.

Ann Chir Plast Esthet. 2013 Dec;58(6):658-62. doi: 10.1016/j.anplas.2011.11.001. Epub 2011 Dec 26. French.

PMID:
22204894
20.

Raynaud's Phenomenon: treatment of a severe case with biofeedback.

Adair JR, Theobald DE.

J Indiana State Med Assoc. 1978 Oct;71(10):990-3. No abstract available.

PMID:
701835

Supplemental Content

Support Center